The American Journal of Medicine
Volume 122, Issue 9 , Pages 857-865 , September 2009

Mortality after Hospitalization with Mild, Moderate, and Severe Hyponatremia

  • Sushrut S. Waikar, MD, MPH

      Affiliations

    • Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • Corresponding Author InformationRequests for reprints should be addressed to Sushrut S. Waikar, MD, MPH, Renal Division, Brigham and Women's Hospital, MRB-4, 75 Francis Street, Boston, MA 02115
    • ,
  • David B. Mount, MD

      Affiliations

    • Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • Renal Division, VA Boston Healthcare System, Boston, Mass
    • ,
  • Gary C. Curhan, MD, ScD

      Affiliations

    • Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass

  • Image Result

    Odds ratios for death in patients with versus without hyponatremia, according to clinical subgroups. Values above one represent a higher risk of death in those with hyponatremia. Odds ratio point esti

    Odds ratios for death in patients with versus without hyponatremia, according to clinical subgroups. Values above one represent a higher risk of death in those with hyponatremia. Odds ratio point estimates are listed above each box, and 95% confidence intervals are represented by solid lines. P values for interaction terms between hyponatremia (Na <135) and the subgroup of interest were as follows: acute myocardial infarction .30, congestive heart failure .57, sepsis .0002, pneumonia <.0001, chronic kidney disease .67, liver disease .004, gastrointestinal bleeding .18, volume depletion .07, metastatic cancer .005, circulatory system (surgical) .69, circulatory system (medical) .02, musculoskeletal system (surgical) .01, nervous system (surgical) .73, nervous system (medical) .26, respiratory system (medical) .002.

 Funding: Investigator-initiated grant from Astellas Pharma US, Inc.

 Conflict of Interest: Dr. Mount reported receiving lecture fees from Astellas Pharma, US, Inc. Astellas had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

 Authorship: Dr. Waikar had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

PII: S0002-9343(09)00280-0

doi: 10.1016/j.amjmed.2009.01.027

The American Journal of Medicine
Volume 122, Issue 9 , Pages 857-865 , September 2009

Article Tools

* Image Usage & Resolution